Voyager Therapeutics, a gene therapy biotech targeting Parkinson's disease and other CNS disorders, announced terms for its IPO on Friday.
The Cambridge, MA-based company plans to raise $75 million by offering 4.7 million shares at a price range of $15 to $17. At the midpoint of the proposed range, Voyager Therapeutics would command a fully diluted market value of $415 million.
Voyager licenses AAV vectors from REGENXBIO (RGNX), which raised $139 million in an upsized September IPO and gained 38% on its first day, but now trades 29% below its offer price.
Voyager Therapeutics, which was founded in 2013 and booked $7 million in collaboration revenue for the 12 months ended June 30, 2015, plans to list on the Nasdaq under the symbol VYGR. Cowen & Company and Piper Jaffray are the joint bookrunners on the deal. It is expected to price during the week of November 9, 2015.
